Safety and immunogenicity of an rAd26 and rAd5 vector-based...

  • Main
  • 2020 / 9
  • Safety and immunogenicity of an rAd26 and rAd5 vector-based...
Lancet (London, England) 2020 / 9

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, Denis Y, Dolzhikova, Inna V, Zubkova, Olga V, Tukhvatullin, Amir I, Shcheblyakov, Dmitry V, Dzharullaeva, Alina S, Grousova, Daria M, Erokhova, Alina S, Kovyrshina, Anna V, Botikov, Andrei G,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Lancet
DOI:
10.1016/S0140-6736(20)31866-3
Date:
September, 2020
File:
PDF, 661 KB
2020
Conversion to is in progress
Conversion to is failed